I’m afraid it could be. There is no obvious fraudulent intentions of the officer(s). There are just missteps, delays and changes in the course. Many folks have alerted the authorities and regulators and nothing has been found. Why is that? Because there is nothing illegal happening. Many companies fail, many companies succeed and many fail at first but end up succeeding. Like Wahoo said, many folks, myself included, look at the last success of Medistem.
Medistem started in 2008 and was sold about five years later. CMTH has been around for several years. They are working on the end game IMO, not a traders desires. What has led us to this point has many reasons.
If all the 9 doctors that signed in 2018 came on line in the fall when we were moving, things would have been fine. Having 3 drop out was not good, but the long delay of switching to CaverStem 2.0 was the big problem IMO. That delayed the remaining doctors from getting up and running until spring 2019. By then the damage was done. The price dropped to .01 and caused more notes to be issued.
Waiting to add the first 100 CaverStem 2.0 patients to the clinical paper was brilliant, but damaging. It caused many of the next round of doctors to hold off and not sign up. Everything flatlined in 2019 waiting on the extended paper. To keep the doors open there were occasional notes for roughly $300,000 to keep the company running.
This is the one thing I agree with Hornet on. It is toxic financing. They cannot get a traditional loan. The notes spiral out of control when they convert lower and lower. I am sure you know that for each tic the PPS dropped, the more shares were needed for each note and on and on. Shorty isn’t stupid, he jumps in like a shark to chum and here we sit. The company didn’t dump shares, the notes did.
No obvious fraudulent intentions of the officer(s), it was the delays and and lack of revs. There is no scam, no fraud, no scheme. It’s a work in progress on their time scale, not ours.
The clinical trial is out now, and it’s clear CaverStem is safe and very effective. There is evidence all around the world that it works. Dig a little and you will find it.
What’s different now? With the clinical trial is out, doctors will be signing up now, FemCelz is ready and StemSpine is ready. In fact, I bet we will all be amazed on what we discover about StemSpine.
The situation is very positive right now. The only question is..... is it too late to save the patient?
I don’t think so and I still have my shares to prove it. I am no fan of a RS, especially in the OTC, but with or without it, CELZ can thrive.
We will know in the next few months.
AI
Market Data 
Markets 
